logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Feb 2021
BioNTech
Completion of phase Ib trial of NEO-PV-01 and Keytruda
Advanced or metastatic nonsquamous non-small cell lung carcinoma
Early 2021
Savara Inc
Top line results from phase III trial of AeroVanc (AVAIL)
Persistent methicillin-resistant Staphylococcus aureus
2021
AIM ImmunoTech Inc.
Data from phase II clinical study combining Ampligen, cisplatin and pembrolizumab
Ovarian cancer
2021
NovoCure
Interim analysis from phase III trial to test the efficacy and safety of TTFields (PANOVA-3)
Pancreatic adenocarcinoma
Q1 2021
ANAPTYSBIO INC
Data from phase II trial of ANB019 (POPLAR)
Palmoplantar pustulosis (PPP)
2021
Orchard Therapeutics plc
Filing of regulatory approval for OTL-103
Wiskott-Aldrich Syndrome
2021
Marinus Pharmaceuticals
Top-line data from single pivotal phase III study evaluating oral Ganaxolone (Violet Study)
Children with PCDH19-Related Epilepsy
after Q1 2021
IDEAYA Biosciences
Interim data from monotherapy arm of the Phase II basket trial of IDE196
Solid tumors harboring GNAQ/11 mutations or PRKC fusions
after Q1 2021
Retrophin Inc.
Top-line data from 36-week interim endpoint efficacy analysis from pivotal phase III clinical trial of Sparsentan (DUPLEX)
Focal segmental glomerulosclerosis
Q1 2021
CohBar, Inc.
Activity readout from Phase 1a/1b clinical trial of CB4211
Nonalcoholic steatohepatitis (NASH) and obesity
Q1 2021
Otonomy Inc.
Top-line results from phase III trial of OTIVIDEX
Ménière's disease
2021
Iovance Biotherapeutics, Inc.
Submission of BLA for Lifileucel
Metastatic melanoma
2021
NovoCure
Final data collection from phase 3 pivotal trial of Tumor Treating Fields (METIS)
Non-small Cell Lung Cancer patients with Brain metastases
2021
Zealand Pharma A/S
Results from phase III trial of Glepaglutide
Short bowel syndrome
Q1 2021
Immunic, Inc
Full data readout from phase II study of IMU-838 (CALDOSE-1)
Ulcerative colitis
2021
Catabasis Pharmaceuticals, Inc.
Filing of NDA for Edasalonexent
Duchenne muscular dystrophy
after Q1 2021
4SC AG
VSE.F
Initial topline data from phase II study of Domatinostat with checkpoint inhibitor (MERKLIN 2)
Second-line Merkel cell carcinoma
2021
Momenta Pharmaceuticals Inc
Top-line data from Phase 2 trial of Nipocalimab (Unity)
pregnant women at high risk for early-onset severe hemolytic disease of the fetus and newborn (HDFN)
2021
GlycoMimetics, Inc.
Top-line results from phase III trial of Uproleselan
Relapsed/refractory AML
2021
Phathom Pharmaceuticals Inc
Topline data from pivotal phase III trial of Vonoprazan (PHALCON-HP)
H. pylori infection
2021
Phathom Pharmaceuticals Inc
Topline data from pivotal phase III clinical trial of Vonoprazan (PHALCON-EE)
Healing of erosive esophagitis (EE) as well as relief of heartburn
2021
BridgeBio Pharma, Inc.
Topline data from phase III trial of Patidegib Topical Gel 2% (BBP-009)
Gorlin Syndrome
after Q1 2021
Equillium Inc.
Data from phase Ib multiple ascending dose trial of Itolizumab (EQUALISE)
Lupus nephritis cohort
after Q1 2021
Dermira Inc.
Topline results from 16-week induction period from two phase III studies of Lebrikizumab
Atopic dermatitis
after Q1 2021
Vir Biotechnology
Data from second flu season of phase I/II clinical trial of VIR-2482
Influenza A